Navigation Links
Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear
Date:10/1/2010

M&A land the resolution of Sanofi-Aventis' bid to acquire Genzyme will continue to unfold after its first offer, valued at $18 billion, was rejected. The fall will also be a very busy time for U.S. drug approvals with over 20 marketing applications to be decided before year's end by the regulators at the U.S. Food and Drug Administration," concluded Burrill.

Biotech IPO Activity

"IPO activity across all sectors picked up in the quarter, but in order to attract investors and get deals done, companies had to be willing to trim their price expectations even in the wake of the strengthening equity markets," noted Burrill.

Three biotech companies amended their prices to go public in the third quarter. Antibiotic developer Trius Therapeutics slashed its expected share price by 62 percent to complete its offering selling 10 million shares at $5 per share. The San Diego biotech plans to begin a late stage trial to evaluate torezolid, its lead next-generation antibiotic, against Pfizer's Zyvox linezolid to treat acute bacterial skin and skin structure infections.

Specialty pharmaceutical company NuPathe raised $50 million after trimming its offering price to $10 from its original $14 to $16 range. NuPathe is focused on treatments for diseases of the central nervous system.

Amyris Biotechnologies, which uses genetically modified yeast to make products for the specialty chemical/fuel markets, raised $85 million by offering 5.3 million shares at $16, below the range of $18-$20. However, its post-IPO trading was positive with the company's shares closing the month up 7.8 percent. Amyris plans to continue its growth through alliances with big-cap companies and has focused on using Brazil's vast resources of sugar cane to help create products. The company plans to use proceeds of the IPO for capital spending, working capital and corporate purposes, including the construction of engineering service capabilities to support sugar and etha
'/>"/>

SOURCE Burrill & Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
2. The Number of Biotechnology Companies has Only Decreased by 10% Despite the Crisis
3. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
4. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
5. NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
6. Nanobiotechnology experts join forces to improve TB testing
7. Sanofi Pasteur to Acquire VaxDesign, a U.S. Biotechnology Company
8. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
9. Kevin Kruse Named Executive Director of the Society of Pharmaceutical and Biotech Trainers
10. Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio
11. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014   ISN has ... Safety Performance Indicators publication series. With data ... activity reported in 2013 within its online contractor management ... safety key performance indicator (KPI) statistics. ... U.S. publication is available in two industry ...
(Date:12/17/2014)... York, NY (PRWEB) December 16, 2014 ... significant changes since 2013, which is why IBISWorld updated ... this industry continues to benefit from an intensified focus ... the proposal for new emission standards for power plants ... industry operators. According to IBISWorld Industry Analyst Sarah Kahn, ...
(Date:12/17/2014)... 2014 “Never say, ‘I cannot ... Marburg’s Department of Physics, advises young women pursuing ... released SPIE Women in Optics 18-month planner ... to ask questions.” , In the annual planner, ... occupations ranging from university professor and laboratory researcher ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... August 28 XTL Biopharmaceuticals,Ltd. (NASDAQ: XTLB ... in the acquisition, development and commercialization of,therapeutics for ... and hepatitis C, today announced that issuances of,American ... bank,The Bank of New York, will be processed ...
... for,Lifesaving Cures revealed today a consequence of the ... by opponents of embryonic stem,cell research: It is ... exclude Missourians with common chromosomal abnormalities like Down,Klinefelter ... In their blind rush to put their ...
... 2 (DRC) announced,today the purchase of 25% of ... for $92.5M. DRC will also provide a $15M,milestone ... be met.,PEG-INTRON (peginterferon alpha-2b), is approved for the ... Schering-Plough Corporation (SGP). Speaking on behalf of ...
Cached Biology Technology:Processing Fees on ADRs to be Waived for two Months 2Processing Fees on ADRs to be Waived for two Months 3New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human 2Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... The Scripps Research Institute have found evidence in laboratory ... recognize methamphetamine and boost tolerance to the drug through ... human studies, could help explain why chronic users go ... as speed. The study could lead to new treatments ...
... "dead zone" area of the Gulf of Mexico ?a region ... huge marine life losses ?has appeared much earlier this year, ... marine life more adversely than normal, researchers are reporting. , ... at Galveston, Louisiana State University and NASA recently surveyed the ...
... little follow-up on open access publishing and the ... The final National Institutes of Health (NIH) rule on ... of federal research dollars and a missed opportunity to ... to a group of the nation's leading not-for-profit medical ...
Cached Biology News:Chemists identify immune system mechanism for methamphetamine binges 2Chemists identify immune system mechanism for methamphetamine binges 3Dead zone area in Gulf could be increasing, researchers say 2Not-for-profit publishers call NIH public access rule a missed opportunity 2Not-for-profit publishers call NIH public access rule a missed opportunity 3
... FHS-LVF, and the CVD-Diffuse We've combined ... Filters to create the world's first notch ... adjustable bandpass. Each filter features an excellent ... These filters -- with interference coatings ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Ms anti-Cyclophilin D...
Protein Kinase D2 Immunogen: Human protein kinase D2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: